Q1 Investor Summit Virtual Format: Presentation Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET Webcast: ...
A study of 151 patients with carbapenem-nonsusceptible infections found treatment with imipenem/cilastatin/relebactam was ...
The owners told authorities that they fed their cats Wild Coast Raw pet food, the same brand implicated in recent feline ...
The following is a summary of “Discrepancies in Beta-Lactam Antibiotics Cross-Reactivity: Implications for Clinical Practice,” published in the February 2025 issue of European Journal of Allergy and ...
Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its p ...
Our Bureau, Bengaluru Tuesday, February 25, 2025, 14:45 Hrs [IST] ...
Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a ...
Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to ...
Venus Remedies rose 2.15% to Rs 313.65 after the company said it secured exclusive in-licensing rights from UK's Infex Therapeutics to develop and commercialize MET-X in India.
The global penicillin drug market size was valued at US$ 8.71 billion in 2023 and is projected to reach US$ 12.08 billion by 2032, registering a CAGR of 3.7% during the forecast period from 2024 to ...
CrisprBits' latest study, published in Nature Scientific Reports, showcases PathCrisp’s ability to detect carbapenem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback